We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Blood Clotting Anomalies Reveal Renal Failure Risk in COVID-19

By HospiMedica International staff writers
Posted on 26 May 2020
Two specific blood-clotting tests identify critically ill COVID-19 patients at high risk for developing renal failure, venous blood clots, and other complications, according to a new study. More...


Researchers at the University of Colorado Anschutz Medical Campus (CUAnshcutz; Aurora, USA) conducted a study that involved 44 intensive care unit (ICU) patients with COVID-19 diagnoses that underwent thromboelastography (TEG; a whole blood assay that provides a broad picture of how a patient’s blood forms clots, including clotting times, how strong the clots are, and how soon clots break down), as well as conventional coagulation assays, D-dimer levels, and viscoelastic parameters, all analyzed to predict thromboembolic outcomes and new onset renal failure.

The results showed that patients identified by TEG assays showing no clot breakdown after 30 minutes and a D-dimer level greater than 2600 ng/mL most often required hemodialysis and had a higher rate of clots in the veins. Overall, 80% of patients with both affirmative test findings were placed on dialysis, compared to 14% who tested for neither finding. Patients with affirmative test findings also had a 50% rate of venous blood clots compared with zero percent for those patients with neither finding. The study was published on May 8, 2020, in the Journal of the American College of Surgeons.

“Fibrinolysis shutdown, as evidenced by elevated D-Dimer and complete failure of clot lysis at 30 minutes on TEG, predicts thromboembolic events and need for hemodialysis in critically ill patients with COVID-19,” concluded lead author Franklin Wright, MD, and colleagues. “These study results suggest there may be a benefit to early TEG testing in institutions that have the technology to identify COVID-19 patients who may need more aggressive anticoagulation therapy to prevent complications from clot formation.”

Patients who are critically ill (regardless of cause) can develop a condition known as disseminated intravascular coagulation (DIC). The blood of these patients initially forms many clots in small blood vessels. The body’s natural clotting factors can form too many clots, and eventually may not be able to effectively form any more clots, leading to issues of both excessive clotting and excessive bleeding.

Related Links:
University of Colorado Anschutz Medical Campus


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.